On 12 Nov 2026 Cardinal Health closed at $278.14, +36.6% this year; market cap $64.81bn, P/E 35.6.
Health Care · Health Care Distributors · NYSE · United States
Cardinal Health, Inc. operates as a healthcare services and products company in the United States and internationally. It operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company offers customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. It distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The company also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; pharmacy management services to hospitals; operates pharmacies, including pharmacies in community health centers; and repackages generic pharmaceuticals and over-the-counter healthcare products. In addition, it manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compression, incontinence, nutritional delivery, and wound care products; single-use surgical drapes, gowns, and apparel products; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. Further, the company distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile and non-sterile procedure kits. Additionally, it manufactures, prepares, and delivers radiopharmaceuticals; and optimizes direct shipments through integrated technology solutions. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
| Market cap | $64.81bn |
| P/E (trailing) | 35.6 |
| EPS (TTM) | $7.80 |
| Beta | 0.52 |
| Dividend | $2.06 |
| Dividend yield | 0.74% |
| Ex-dividend date | 1 Oct 2026 |
| Latest report | 5 Nov 2026 |
| Next earnings | 4 Feb 2027 |
| YTD | +36.6% |
| 1Y | +37.4% |
| 3Y | +40.4% |
| 5Y | +43.0% |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2026 | $254.25bn | $1.71bn | $4.53bn |
| 2025 | $222.58bn | $1.56bn | $1.85bn |
| 2024 | $226.83bn | $852.00m | $3.25bn |
| 2023 | $204.98bn | $330.00m | $2.36bn |
| 2022 | $181.33bn | $-938.00m | $2.73bn |
We publish no single base value for Cardinal Health. Our valuation methods put it between $160.69 and $474.44 a share. The valuation code's reason: no point fair value: the two anchors behind it compound the same growth rate and differ only in how they end — a perpetuity at the terminal rate against a multiple on the final year — so the midpoint between them measures terminal treatment rather than what the business is worth. The published range is the same reading with the false precision removed: read it as the span the method supports, and treat neither edge as a point estimate. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.